Canavan Disease Treatment Market to Expand with Significant CAGR by 2025

Canavan-van Bogaert-Bertrand or Canavan disease is a rare and fetal genetic condition. It is an autosomal recessive condition that causes damage to cells of nervous system in the brain. It is a common progressive cerebral disease in newborns. Canavan disease is caused by the lack of aminoacylase 2 enzyme. Canavan disease is one of the disease condition in leukodystrophies. Leukodystrophies is a set of genetic diseases caused by the damaged myelin sheath or abnormal growth of myelin sheath. Erosion of myelin in the phospholipid layer is one of the major characteristics of Canavan disease. Phospholipid layer is an insulating layer of axons of neuron, linked with a gene located on human chromosome.

Symptoms of Canavan disease appear just after birth and become worse quickly. These include poorly controlled head movement, an abnormally large head, unusual muscle tone, loss of muscle coordination, and mental disabilities. Other symptoms include paralysis, blindness, and hearing loss, deterioration of the optic nerves that conduct impulses from the nerve rich membrane lining of the retina to the optic atrophy (brain), backflow of acid from the stomach to the throat, occasionally related with vomiting, nasal regurgitation, feeding difficulties, sleep disorders, and seizures. In recent time, a minor type of Canavan disease has been diagnosed, with typical alterations of the aspartoacylase gene and slightly high level of N-Acetylaspartic acid in the urine. Kids with Canavan disease treatment may be somewhat behind, can study and learn.

The head of children with Canavan disease treatment may be slightly increased; however, the distinctively changes of white matter in brain may be absent. Canavan disease affects both females and males in same amount. Canavan disease affects whole ethnic crowds, but arises with larger occurrence in persons of Ashkenazi Jewish descent. In the population of these descent, carrier frequency is projected to be great as one out of 40-58 persons. The risk of child born with canavan disease from Ashkenazi Jewish parents is in between 1 out of 6,400 and 1 out of 13,456. The incidence of carrier in other people is unknown, but most probable extreme less. The global Canavan Disease Treatment Market is driven by increase in incidence rate globally. Genetic mutations is another driver of the market. However, the lack of awareness about the disease is one of the major restraints of the market. Absence of proper treatment is another restraint of the global Canavan disease treatment market.

Request to View Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=41099

The global Canavan disease treatment market can be segmented based on type of treatment, end-user, and region. In terms of type of treatment, the Canavan disease treatment market can be classified into gene therapy and drug therapy. The drug therapy segment can be classified into anticonvulsants and others. Based on end-user, the global Canavan disease treatment market can be categorized into hospitals, surgical clinics, and others.

In terms of region, the global Canavan disease treatment market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is expected to dominate the global Canavan disease treatment market due to availability of advanced medical facilities. Awareness among the people about the diseases is another factor boosting the market in this region. The Canavan disease treatment market in Asia Pacific is anticipated to expand at a high growth rate due to increase in prevalence of the disease. Lack of awareness about the disease in the underdeveloped countries in Middle East & Africa such as Turkey, Cyprus, Syria, Lebanon, and Iraq propels the Canavan disease treatment market.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=41099

Key players operating in the global Canavan disease treatment market are Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Sanofi, F. Hoffmann-La Roche Ltd., and Amgen, Inc., among others.

Comments

comments

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *